<DOC>
	<DOCNO>NCT01588015</DOCNO>
	<brief_summary>This randomized phase I trial study side effect vaccine therapy prevent cytomegalovirus ( CMV ) infection patient hematological malignancy undergo donor stem cell transplant . Vaccines make tetanus-CMV peptide antigen may help body build effective immune response prevent delay recurrence CMV infection patient undergo donor stem cell transplant hematological malignancy .</brief_summary>
	<brief_title>Vaccine Therapy Preventing Cytomegalovirus Infection Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To discover whether two administration 2.5 mg tetanus ( Tet ) -CMV peptide co-injected 1 mg PF-03512676 ( tetanus-CMV fusion peptide vaccine ) , subcutaneous ( SC ) route day 28 56 post-hematopoietic cell transplantation ( HCT ) safe well tolerate human leukocyte antigen ( HLA ) A*0201 CMV-positive recipient allogeneic HCT . SECONDARY OBJECTIVES : I . To measure level CMV-specific T cell vaccinate compare unvaccinated HCT recipient ( control arm ) . II . To assess whether vaccination HCT recipients Tet-CMV co-injected PF03512676 reduces expression program death 1 ( PD-1 ) CMV-specific T cell . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive Tet-CMV + PF03512675 SC day 28 56 post-HCT . ARM II : Patients undergo immune monitoring . After completion study treatment , patient follow day 70 , 84 , 100 , 130 , 160 , 180 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>HLA A*0201 subtype CMV seropositive Able willing sign inform consent form ( ICF ) Willingness follow plan duration trial ( 6 month postHCT ) Seronegative human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) active hepatitis B virus ( HBV ) ( surface antigen negative ) Planned relate unrelated HCT , 8/8 7/8 ( A , B , C , DRB1 ) high resolution HLA donor allele match HCT treatment hematologic cancer include , limited : Acute lymphoblastic leukemia first second remission ( acute lymphoblastic leukemia/lymphoblastic lymphoma , disease status need hematologic remission bone marrow/peripheral blood ; persistent lymphadenopathy compute tomography [ CT ] CT/positron emission tomography [ PET ] scan without progression allow ) Chronic myelogenous leukemia first chronic accelerated phase , second chronic phase Hodgkin nonHodgkin lymphoma Myelodysplastic syndrome Planned HCT minimal noT cell depletion graft Use contraception 90 day postHCT Negative pregnancy test female recipient DISEASE STATUS : Recipients enrol patient eligible allogeneic HCT , diagnose hematologic cancer include : Acute lymphoblastic leukemia ( ALL ) ; Bprecursor ALL ; T cell ALL Acute myeloid leukemia ( AML ) , acute promyelocytic leukemia ; treatment related AML Chronic lymphoid leukemia ; adult T cell leukemia/lymphoma , chronic lymphocytic leukemia otherwise specify ( NOS ) , hairy cell leukemia ; prolymphocytic leukemia ( B T ) ; T cell large granular ( gran . ) lymphocytic ( lymph . ) leukemia ( leuk ) Chronic myeloproliferative disease ( CML ) ; chronic eosinophilic leukemia ( CEL ) /hypereosinophilic syndrome ; chronic idiopathic myelofibrosis ; CML Philadelphia chromosome ; essential thrombocythemia ; polycythemia vera Leukemia , otherwise specify ( NOS ) Myelodysplastic syndrome , NOS ; chronic myelomonocytic leukemia Hodgkin lymphoma , NOS ; Hodgkin lymphoma nodular lymphocyte predominant ( LP ) , NOS ; Hodgkin lymphoma like posttransplant lymphoproliferative disorder ( PTLD ) Lymphoma , NOS NonHodgkin lymphoma ( NHL ) ; anaplastic largecell lymphoma ( ALCL ) , cutaneous , ALCL , systemic ; Burkitt lymphoma/leukemia ; cutaneous Tcell lymphoma ( CTCL ) /mycosis fungoides ; CTCL/Sezary syndrome ; diffuse large Bcell lymphoma ; mucosa associate lymphoid tissue ( MALT ) lymphoma ; extranodal natural killer ( NK ) /T cell lymphoma , extranodal NK/T lymphoma nasal ; follicular lymphoma ; lymphoplasmacytic lymphoma mantle cell lymphoma ; mediastinal large Bcell lymphoma ; nodal marginal zone Bcell lymphoma ( lymph . ) ; NHL aggressive , NOS ; NHL indolent , NOS ; NHL , NOS ; peripheral T cell lymphoma , NOS ; PTLD ( monoclonal ) ; PTLD ( polyclonal ) ; precursor ( precur . ) Blymphoblastic lymphoma ; precur Tlymphoblastic lymphoma ; primary central nervous system ( CNS ) lymphoma ; primary effusion lymphoma ; small lymphocytic lymphoma , NOS Myeloma , NOS ; monoclonal gammopathy undetermined significance ( MGUS ) ; solitary plasmacytoma Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow duration study participation ; woman become pregnant suspect pregnant participate trial , inform treat physician immediately All medication , supportive care , blood product radiation therapy take administered trial document subject 's clinical/hospital case report form ( CRF ) , use City Hope ( COH ) guideline ; subject 's clinical information record appropriate CRF Concurrent enrollment clinical trial use investigational product prohibit The use alemtuzumab immunosuppression permit study Prophylactic therapy CMV immunoglobulin prophylactic antiviral CMV treatment allow Medications might interfere evaluation investigational product administer , 30 day prior participation trial 14 day second vaccination ( day 70 postHCT ) ; medication category include , limited : Live attenuate vaccine Medically indicate subunit ( EngerixB HBV ; Gardasil HPV ) kill vaccine ( e.g . influenza , pneumococcal , allergy treatment antigen injection ) Antiviral treatment herpes simplex virus ( HSV ) , human herpes virus 6 ( HHV6 ) , EpsteinBarr virus ( EBV ) adenovirus include use GVC/VAL , FOS , Cidofovir , CMX001 may also suppress reactivation CMV , thus allow study ; patient require treatment randomization ( day 28 ) remove study replace ; reason removal report patient 's CRF All enrol recipient require antiCMV therapy day 28 replace , treat monitor require COH standard care ; GVC/VAL , FOS , Cidofovir , CMX001 may use accord COH standard care ( SOC ) preemptive management CMV viremia ; antiviral treatment require day 28 , plan 2nd vaccine injection day 56 administer ( vaccine arm ) All subject must ability understand willingness sign write informed consent A poorrisk patient , define follow : Chronic myelogenous leukemia blast crisis Acute myeloid leukemia beyond second remission Multiple myeloma Aplastic anemia Planned immunosuppression alemtuzumab equivalent vivo Tcell deplete agent In vitro T cell deplete graft Planned prophylactic therapy CMV immunoglobulin Planned CMV prophylactic therapy Experimental antiCMV chemotherapy last 6 month Diagnosed autoimmune disease Receipt follow substance : Any prior investigational CMV vaccine Live attenuate vaccine , medically indicate subunit kill vaccine 30 day prior participation trial 14 day second vaccination ( day 70 postHCT ) Investigational research product allergy treatment antigen injection 30 day prior participation trial 14 day second vaccination ( day 70 postHCT ) Pregnant and/or breast feed female recipient Refusing use contraception 90 day postHCT POSTHCT STUDYSPECIFIC EXCLUSIONS : On day 28 56 postHCT ( immunization day vaccine arm ) study recipient ( vaccine observation arm ) review eligibility rule ineligible initiate continue study receive vaccination ( vaccine arm ) : Diagnosed &gt; grade 2 graftversushost disease ( GVHD ) day 28 postHCT , diagnose &gt; grade 2 GVHD day 28 postHCT administration 2nd vaccine day 56 Received steroid therapy prednisone &gt; 1 mg/kg/day , less 7 day prior injection Had relapse Experience graft failure ( absolute neutrophil count &lt; 500/mm^3 ) Received antiviral treatment GVC/VAL , FOS , Cidofovir , CMX001 point 28 day period There ongoing nonhematological postHCT toxicity &gt; = grade 3 nonhematological ( hem ) adverse event ( AE 's ) , exception grade 3 glucose intolerance grade 3 nonhem lab ; cholesterol , triglyceride , hyperglycemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>